PDCD1 and Miyoshi myopathy: Immune‐related adverse events (irAEs) occur in approximately 60%–80% of patients with MM receiving PD‐1 monotherapy [1, 7, 8], and serious irAEs affect approximately 10%–20% of these patients [1, 2, 7, 8, 9].